[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360067-105":59,"doc-detail-360067-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","neoantigen-targeting-as-a-novel-approach-for-therapyresistant-tumors","Neoantigen Targeting as a Novel Approach for Therapy‑Resistant Tumors","","Neoantigens are positioned as central targets for individualized cancer vaccines because the immune system recognizes them as foreign and can drive strong anti-tumor responses. Computational advances and machine learning improve neoantigen prediction, while clinical trials show promise for vaccines using validated neoantigens delivered as peptides, RNA, or dendritic cells. Key bottlenecks remain the multi-step process of identifying immunologically effective candidates and confirming cytotoxic T lymphocyte activation. Expression and immune responses are further shaped by tumor-intrinsic and therapy-related factors, including PD‑L1 suppression and ARID1A-linked chemoresistance-associated neoantigen upregulation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neoantigen-targeting-as-a-novel-approach-for-therapyresistant-tumors/360067/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neoantigen-targeting-as-a-novel-approach-for-therapyresistant-tumors/360067.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are neoantigens considered important targets for cancer immunotherapy?","Question",{"text":113,"@type":114},"Neoantigens are recognized by the immune system as foreign and can elicit potent, tumor-specific anti-tumor responses, making them strong candidates for individualized vaccine strategies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What makes identification of immunologically effective neoantigens difficult?",{"text":118,"@type":114},"Even with improved computational prediction, determining immunogenic candidates remains a complex multi-step process that must verify cytotoxic T lymphocyte activation, while accounting for factors like HLA polymorphisms and antigen expression patterns.",{"name":120,"@type":111,"acceptedAnswer":121},"How can therapy and tumor-intrinsic factors affect neoantigen expression and immune responses?",{"text":122,"@type":114},"Neoantigen presentation and immune recognition are influenced by tumor-intrinsic and therapeutic factors, including high PD‑L1 expression that suppresses recognition and ARID1A mutations that can enhance neoantigen expression during chemoresistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360067,1790781741,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Molecular Diagnosis & Therapy (2026) 30:495–514 [https://doi.org/10.1007/s40291-026-00842-9](https://doi.org/10.1007/s40291-026-00842-9)  \nNeoantigen Targeting as a Novel Approach for Therapy‑Resistant Tumors  \nMasahiro Okada1 · Satoru Yamasaki1 · Go R. Sato1 · Kanako Shimizu1 · Shin‑ichiro Fujii1,2  \nReceived: 6 October 2025 / Accepted: 22 February 2026 / Published online: 30 March 2026 © The Author(s) 2026  \nAbstract  \nNeoantigens have emerged as central targets in the development of individualized cancer vaccines, as they are recognized by the immune system as foreign and can elicit potent anti-tumor responses. Advances in computational algorithms and machine learning have improved the accuracy of neoantigen prediction, and clinical trials have reported promising results of vaccines incorporating validated neoantigens into peptide, RNA, or dendritic cell platforms. Despite this progress, the identification of immunologically effective neoantigens remains a complex multi-step process. Current attention is directed not only to conventional missense and indel mutations but also to non-coding RNA-derived neoantigens. A critical challenge is the establishment of reliable systems to verify whether candidate neoantigens can activate cytotoxic T lymphocytes. Moreover, neoantigen expression and immune responses are influenced by tumor-intrinsic and therapeutic factors. High programmed death-ligand 1 expression is known to suppress immune recognition, while ARID1A mutations, associated with tumor progression, can enhance neoantigen expression during chemoresistance, suggesting that drug resistance may be accompanied by new immunogenicity. This work provides an overview of current methodologies for neoantigen identification, advances in prediction and validation strategies, and the dynamic interplay between tumor-intrinsic and immune-related factors that regulate neoantigen expression. We also highlight recent clinical insights as well as novel analytical approaches and discuss challenges and future directions in this rapidly evolving field, emphasizing the potential of neoantigen-based therapies to transform cancer immunotherapy.  \nKey Points  \nNeoantigens can arise from various changes in gene sequence and expression, including missense mutations, short insertions and deletions (indels), gene fusions, aberrant splicing events, virus-derived sequences, and non-coding regions of the genome.  \nNeoantigens have been identified as highly specific and potent targets capable of inducing tumor-specific T-cell responses. Currently, research focuses on identifying and characterizing neoantigens with strong immunogenicity.  \nNeoantigens have been clinically exploited through various modalities, including peptide vaccines, messenger RNA platforms, and T-cell receptor-engineered T-cell therapies.  \n1 Introduction  \nCancer remains a major global health challenge, causing approximately 10 million deaths annually, and ranking asthe second leading cause of mortality worldwide. Breast, lung, colorectal, and prostate cancers are the most frequently diagnosed types, highlighting the urgent need for innovative therapeutic strategies. In addition to conventional chemotherapy and radiotherapy, immunotherapy has emerged as a transformative paradigm-shifting approach in cancer treatment. Immunotherapy can achieve durable tumor control by modulating the tumor microenvironment and harnessing the immune system of the patient. The advent of immune checkpoint inhibitors (ICIs) has marked a breakthrough in cancer treatment, although their efficacy is not robust across patients.  \n* Shin-ichiro Fujii [shin-ichiro.fujii@riken.jp](shin-ichiro.fujii@riken.jp)  \n1 Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Sciences, 1-7-22, Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  \n2 RIKEN Program for Drug Discovery and Medical Technology Platforms, RIKEN, Yokohama, Kanagawa, Japan  \nRecent advances in cancer immunotherapy encompass a broad ","cbCainPm7Tr5FUzl","https://ap.wps.com/l/cbCainPm7Tr5FUzl","pdf",1329391,"English","# Abstract\n# Key Points\n# 1 Introduction","[{\"question\":\"Why are neoantigens considered important targets for cancer immunotherapy?\",\"answer\":\"Neoantigens are recognized by the immune system as foreign and can elicit potent, tumor-specific anti-tumor responses, making them strong candidates for individualized vaccine strategies.\"},{\"question\":\"What makes identification of immunologically effective neoantigens difficult?\",\"answer\":\"Even with improved computational prediction, determining immunogenic candidates remains a complex multi-step process that must verify cytotoxic T lymphocyte activation, while accounting for factors like HLA polymorphisms and antigen expression patterns.\"},{\"question\":\"How can therapy and tumor-intrinsic factors affect neoantigen expression and immune responses?\",\"answer\":\"Neoantigen presentation and immune recognition are influenced by tumor-intrinsic and therapeutic factors, including high PD‑L1 expression that suppresses recognition and ARID1A mutations that can enhance neoantigen expression during chemoresistance.\"}]","Neoantigen Targeting as a Novel Approach for Therapy‑Resistant Tumors | PDF",1790138673,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54a572ba99a9365c7f53d6292ce9a501.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d362b62b5a28a84ba36460b591323419.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/472e210ea2585fe807e0911b385bc4dc.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7472e215105a0928ef5a4b2461c36fb6.webp",980,1301]